Revolution Medicines (RVMD) Non Operating Income (2019 - 2026)
Revolution Medicines' quarterly Non Operating Income came in at -$8.6 million in Q1 2026, down 85840.0% year-on-year from N/an in Q1 2025, and down 116.81% quarter-over-quarter from $51.1 million in Q4 2025.
Revolution Medicines has reported Non Operating Income for 8 years, with the latest figure at -$8.6 million in Q1 2026.
- For the quarter ending Q1 2026, Non Operating Income fell 85840.0% year-over-year to -$8.6 million; the trailing twelve-month figure through Mar 2026 stood at $59.4 million (down 55.64% YoY), and the FY2025 full-year result was $51.1 million, down 42.41% from the prior year.
- Non Operating Income for Q1 2026 stood at -$8.6 million, down from $51.1 million in the prior quarter.
- The five-year high for Non Operating Income was $91.2 million in Q4 2024, with the low at -$8.6 million in Q1 2026.
- Average Non Operating Income over 5 years is $17.2 million, with a median of $8.8 million recorded in 2023.
- Year-over-year, Non Operating Income jumped 2237.42% in 2023 and tumbled 85840.0% in 2026.
- Tracing RVMD's Non Operating Income over 5 years: stood at $5.1 million in 2022, then soared by 831.53% to $47.3 million in 2023, then soared by 92.81% to $91.2 million in 2024, then sank by 43.95% to $51.1 million in 2025, then tumbled by 116.81% to -$8.6 million in 2026.
- The last three Non Operating Income figures came in at -$8.6 million (Q1 2026), $51.1 million (Q4 2025), and $16.9 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 444,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 201.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -46.98 Mn |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - | -8.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8.59 Mn |
| Dec 31, 2025 | 51.11 Mn |
| Jun 30, 2025 | 16.93 Mn |
| Mar 31, 2025 | -10,000.00 |
| Dec 31, 2024 | 91.19 Mn |
| Sep 30, 2024 | 19.42 Mn |
| Jun 30, 2024 | 23.41 Mn |
| Mar 31, 2024 | -2.81 Mn |
| Dec 31, 2023 | 47.29 Mn |
| Sep 30, 2023 | 10.95 Mn |
| Jun 30, 2023 | 10.50 Mn |
| Mar 31, 2023 | 7.06 Mn |
| Dec 31, 2022 | 5.08 Mn |
| Sep 30, 2022 | 2.91 Mn |
| Jun 30, 2022 | 867,000.00 |
| Mar 31, 2022 | 302,000.00 |
| Dec 31, 2021 | 237,000.00 |
| Sep 30, 2021 | 223,000.00 |
| Jun 30, 2021 | 236,000.00 |
| Mar 31, 2021 | 221,000.00 |
| Dec 31, 2020 | 238,000.00 |
| Sep 30, 2020 | 330,000.00 |
| Jun 30, 2020 | 711,000.00 |
| Mar 31, 2020 | 888,000.00 |
| Dec 31, 2019 | 595,000.00 |
| Sep 30, 2019 | 741,000.00 |
| Jun 30, 2019 | 442,000.00 |
| Mar 31, 2019 | 305,000.00 |